Brazil accuses Gilead over 1,421.5% price hike of hep C drug

The Brazilian Federal Public Defender’s Office has filed a complaint against Gilead for hugely increasing the price of its hepatitis C drug since it gained patent protection.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

USPTO director steps into Sun Pharma’s PTAB-ITC clash

31 July 2026 A director review has overturned a PTAB ruling, questioning why it diverged from an ITC decision based on the same patent claims, prior art and evidence.

Pharma

Pharmascience v Janssen: Canada court updates methods of medical treatment protection

23 July 2026 Canada has firmly slammed the door on patenting methods of medical treatment—but the battle over what counts as a "medical method" is only just beginning. Scott MacKendrick of ROBIC examines a landmark decision that leaves the door ajar for future litigation over complex drug-dosing regimens.

Pharma

Exelixis opens two-front patent dispute over Cabometyx copies

9 July 2026 Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.

More features

USPTO director steps into Sun Pharma’s PTAB-ITC clash

USPTO appoints new acting commissioner for patents

European court strikes down hearing aid sensor patent

Where Big Pharma is betting big in the M&A boom

Fish & Richardson adds AI and medical device specialist

Boston Scientific overturns $42m patent verdict on appeal

Buying the brains: Why is Big Pharma shopping for innovation?

FisherBroyles and Hong Kong affiliate draft in senior partners

Brazil accuses Gilead over 1,421.5% price hike of hep C drug

More on this story

Editor's picks

Editor's picks

More features